- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
More ▼
Key statistics
As of last trade Roche Holding AG (RHO6:FRA) traded at 28.01, 1.10% above its 52-week low of 27.70, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.00 |
---|---|
High | 28.01 |
Low | 28.00 |
Bid | 28.00 |
Offer | 28.44 |
Previous close | 28.00 |
Average volume | 169.11 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 15.32 |
Market cap | 195.72bn USD |
EPS (TTM) | 1.96 USD |
Annual div (ADY) | 1.31 EUR |
---|---|
Annual div yield (ADY) | 4.31% |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 27 2023 |
Data delayed at least 15 minutes, as of Apr 26 2024 14:52 BST.
More ▼